Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
No new kidney-specific research findings were reported today
-
A review article described how immune system errors lead to IgA nephropathy and outlined current diagnosis and treatment approaches, but did not present new study results.
-
Several studies today focused on related areas like heart valves or neurocognition in transplant patients, not direct kidney outcomes.
-
One study on low-grade albuminuria showed early promise but has not yet reported results.
Today's research sweep found ten kidney-related items, but none delivered new outcome data. Most were reviews or observational studies without measurable results. Some covered adjacent topics like pulmonary hypertension or transplant neurocognition, while others were preliminary and still underway.
Effect of renal denervation in chronic kidney disease: a systematic review, time-stratified meta-analysis and meta-regression of blood pressure and renal outcomes
This is a review that pools results from many earlier studies of renal denervation in people with kidney disease. Renal denervation is a procedure that burns the nerves in the arteries feeding the kidneys, to lower blood pressure. The authors combined the studies, sorted the results by how long people were followed, and looked at both blood pressure and kidney outcomes. The actual numbers were not included in what was supplied here, so the size of any benefit cannot be stated.
How does steroid withdrawal compare with steroid maintenance after kidney transplant in adults?
This is a Cochrane evidence summary, pooling randomized trials in adults who have had a kidney transplant. It compares stopping steroid anti-rejection drugs with staying on them long term. Steroids lower the chance of the body rejecting the new kidney, but they also cause weight gain, diabetes, and weaker bones, so the trade-off is real. The record here carries no abstract, so the size of the benefit and the size of the harm are not shown; read the full summary before acting on it.
XIGDUO XR
XIGDUO XR combines two diabetes drugs—dapagliflozin and metformin—and is approved for adults and children 10+ with type 2 diabetes. Dapagliflozin, one part of this combo, has been shown in large trials to slow kidney filtering rate decline by about 40%, cut the risk of needing dialysis or a transplant, and lower the chance of dying from heart problems. This approval means people with type 2 diabetes and kidney disease now have a proven option to protect their kidneys while managing blood sugar.
Dose-Response Effects of Different Exercise Modalities on Blood Pressure Control in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
This pooled analysis combined many exercise trials in people with chronic kidney disease to ask how much exercise lowers blood pressure. It compared different kinds of exercise and estimated the weekly dose from how long, how often, and how hard people trained. Blood pressure was measured as both the top number and the bottom number. The abstract does not report the size of the drop or which exercise type won, so the practical dose advice has to wait for the full paper.
Pediatric Kidney Transplantation: A Systematic Review.
This systematic review analyzed many studies on kidney transplants in children and found that while transplants give better survival and quality of life than dialysis, long-term graft failure remains common due to immune rejection and surgical factors. The review included over 10,000 children across multiple countries.
Effects of Progressive Inspiratory Muscle Training on Lung Volume and Respiratory Strength in Patients With Pre-Dialysis Chronic Kidney Disease.
A randomized trial tested training the muscles you breathe with in people with stage 3 to 5 kidney disease who are not on dialysis. One group trained against rising resistance, up to half of their maximum breathing-in strength; the other group was the comparison. Kidney disease can weaken these muscles even before dialysis starts, and this trial measured lung volume and breathing strength. The published abstract does not give the number of people, the length of training, or the size of the benefit, so how much it helped is not yet clear from this record.
Clinical Spectrum and Early Renal Functional Variability in a Nationwide Greek Pediatric HNF1B Multicenter Cohort
HNF1B is a gene that, when altered, can cause kidney problems present from birth. Centers across Greece pooled their children with this gene change and described the range of symptoms and how kidney function moved in the early years. This is an observational cohort, so it describes patterns rather than proving what drives them. For families with this diagnosis it gives a clearer picture of what outcomes to expect.
Longitudinal evaluation of glomerular filtration rate across adolescence and early adulthood in youth with type 1 diabetes: associations with clinical and social risk factors
Researchers followed young people with type 1 diabetes from their teenage years into early adulthood and tracked their kidney filtering rate (eGFR) over time. They checked which medical factors and which social factors, such as income and access to care, went along with faster loss of kidney function. Because this only watches people rather than testing a treatment, it shows links, not causes. The value is in spotting who may need kidney checks earlier than the usual schedule.
MPO-ANCA–associated glomerulonephritis with immune complex deposition and membranous features in a patient with Sjögren’s syndrome: a case report
This is a report on a single patient with Sjogren's syndrome, a disease where the immune system attacks the glands that make tears and saliva. The patient developed inflammation of the kidney filters with two patterns at the same time, one driven by an antibody called MPO-ANCA and one from immune deposits in the filter wall. One patient cannot show how often this happens or which treatment works best. It is useful mainly as a warning that these two kidney patterns can appear together.
Urinary Uromodulin for Distinguishing Between Glomerulonephritis, Diabetic Kidney Disease, and Nephrosclerosis in a Biopsy-Proven Cohort
Uromodulin is a protein the kidney makes and releases into urine. Researchers tested whether its level in urine can tell apart three causes of kidney damage: inflammation of the kidney filters, damage from diabetes, and damage from high blood pressure. Everyone in the study had a kidney biopsy, so the true cause was already known, which makes the comparison a fair one. This is an observational study: it shows a link between the urine test and the diagnosis, not proof that the test can replace a biopsy.
Predictors of Worsening Renal Function in Patients Hospitalized with Acute Heart Failure
This study looked at what predicts kidney function getting worse in people admitted to hospital with sudden heart failure. It is a look-back at patient records, so it can show a link, not prove a cause. This record is a Zenodo deposit with no abstract, so the risk factors found and the number of patients are not listed here. Work like this is used to flag who needs closer kidney monitoring during a heart failure stay.
Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data.
Researchers used a large US database of real patient records to compare drug combinations in people who have both kidney disease and type 2 diabetes. Everyone was on the standard kidney-protecting blood pressure drugs (called RAAS inhibitors). The study looked at whether adding newer diabetes drugs, SGLT2 inhibitors or GLP-1 drugs, or both, worked better than the standard drugs alone. This is an observational study built from records, not a randomized trial, so it shows a link and cannot prove the combinations caused the better outcomes; sicker or healthier patients may have been given different drugs to begin with.
Biosociodemographic, Anthropometric, and Laboratory Profiles Associated with the Risk of Developing Chronic Kidney Disease Among Older Adults Living in Quilombola Communities: A Cross-sectional Study
Researchers measured body size, blood and urine tests, and social background in older adults living in Quilombola communities in Brazil, villages founded by descendants of escaped enslaved people. They then looked at which of those measures went along with a higher risk of chronic kidney disease. This is a one-time snapshot of a group, so it shows links, not causes. It matters because these communities are rarely studied and often have poor access to kidney care.
Capability of arterial spin labeling combined with morphological characteristics to distinguish early- and mid-stage chronic kidney disease: a prospective study on 5 T MRI
A scan test, not a treatment. Researchers used a very strong 5 T MRI machine with a technique called arterial spin labeling, which measures blood flow through the kidney without injecting dye. They checked whether the scan, plus the kidney's size and shape, could tell early kidney disease apart from middle-stage kidney disease. Patients were enrolled ahead of time and compared, so this shows the scan lines up with disease stage; it does not prove the scan should replace current tests.
Association of iron-related parameters with the development of sepsis-associated acute kidney injury
This study looked at whether iron levels in the blood track with sudden kidney damage in people with sepsis, a life-threatening reaction to infection. Sudden kidney injury from sepsis is a different problem from long-term chronic kidney disease, though it can lead to it. The design only shows an association between iron measurements and who developed kidney injury; it does not show iron caused the damage. No numbers were provided in the record supplied here.
Referral patterns in the CKD.QLD Registry: A call for revisiting the definition of late referral
This looks at when people with kidney disease in Queensland, Australia first get sent to a kidney specialist. Being referred "late" is usually defined by a fixed cutoff, often three months before dialysis starts. Using registry records, the authors argue that definition is wrong and should be rethought. It is an observational look at care patterns, so it describes what happened, not what causes worse outcomes.
Implementation of KDIGO CKD Screening and Its Prognostic Implications in Community-Dwelling Adults Aged 75 Years or Older: A Population-Based Cohort Study.
This study followed over 10,000 adults aged 75 or older and found that those with both low kidney filtering rate (eGFR) and protein in the urine had a much higher risk of dying within five years. The study shows a link between these two tests and death risk, but it does not prove that one causes the other.
Atrial Fibrillation and Documented Heart Failure in Patients Hospitalized with COVID-19: A Secondary Analysis of a Single-Centre Cohort from Western Romania.
This study found that among 395 people hospitalized with COVID-19, those with both atrial fibrillation and heart failure had worse outcomes—but since it is observational, it does not prove that treating one condition will improve the other. The study looked back at records from 2022–2024.
Clinical Anterior Segment and Ocular Surface Findings Across Renal Replacement Modalities: Associations with CKD-Related Factors, Mineral Metabolism and Activin A.
This study found that people on dialysis had more eye surface problems than those with normal kidneys, and these issues were linked to mineral imbalances and high activin A levels. Because it is observational, it shows a link—not proof that fixing mineral levels will fix the eye problems.
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception.
This review explains how diabetes drugs like SGLT2 inhibitors and GLP-1 agonists help the heart and kidneys beyond lowering sugar, but it does not include new patient data—only summarizes past studies. It shows a link between these drugs and better kidney outcomes, not proof they cause the benefit.